(4-methyl-1H-pyrazol-1-yl)(piperidin-1-yl)methanone | 1622426-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (4-methyl-1H-pyrazol-1-yl)(piperidin-1-yl)methanone
• 英文别名: Serine Hydrolase Inhibitor-10；(4-methylpyrazol-1-yl)-piperidin-1-ylmethanone
• CAS: 1622426-15-6
• 化学式: C₁₀H₁₅N₃O
• 分子量: 193.249
• InChiKey: OSNDHJDVIJJVOE-UHFFFAOYSA-N

物化性质

• 沸点：
  326.0±35.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  哌啶 、 4-Methylpyrazole-1-carbonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以105 mg的产率得到(4-methyl-1H-pyrazol-1-yl)(piperidin-1-yl)methanone
  参考文献：
  名称：

  N-酰基吡唑：丝氨酸水解酶的有效和可调抑制剂。

  摘要：

  研究了一系列N-酰基吡唑作为候选的丝氨酸水解酶抑制剂，其中不仅可以通过酰基的性质来调节活性位点的酰化反应性和吡唑的离去基能力（反应性：酰胺>氨基甲酸酯>尿素） ，也可以通过吡唑C4取代为吸电子或供电子的取代基。它们对酶抑制活性的影响显示出显着效果，并且随着显着改变反应的羰基（脲>氨基甲酸酯>酰胺）和吡唑C4取代基（CN> H> Me）的性质，其活性显着提高。进一步证明，N-酰基吡唑脲的酰基链可用于调节抑制剂类别对靶向的丝氨酸水解酶的效力和选择性。因此，

  DOI：

  10.1016/j.bmc.2019.03.020

文献信息

• Pyrazole compounds and methods of making and using same
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US10093630B2

  公开（公告）日：2018-10-09

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.

  本文提供了吡唑化合物和包含所述化合物的药物组合物。所述化合物和组合物可用作 MAGL、ABHD6 和 FAAH 中一种或多种的调节剂。此外，所述化合物和组合物还可用于治疗疼痛、实体瘤和/或肥胖症等。
• Discovery libraries targeting the major enzyme classes: The serine hydrolases
  作者：Katerina Otrubova、Venkat Srinivasan、Dale L. Boger

  DOI：10.1016/j.bmcl.2014.06.063

  日期：2014.8

  Two libraries of modestly reactive ureas containing either electron-deficient acyl anilines or acyl pyrazoles were prepared and are reported as screening libraries for candidate serine hydrolase inhibitors. Within each library is a small but powerful subset of compounds that serve as a chemotype fragment screening library capable of subsequent structural diversification. Elaboration of the pyrazole-based ureas provided remarkably potent irreversible inhibitors of fatty acid amide hydrolase (FAAH, apparent Ki=100-200 pM) complementary to those previously disclosed enlisting electron-deficient aniline-based ureas.
• PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US20170190669A1

  公开（公告）日：2017-07-06

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.
• US8524718B2
  申请人：——

  公开号：US8524718B2

  公开（公告）日：2013-09-03
• [EN] PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE PYRAZOLE, PROCÉDÉS DE PRODUCTION ET UTILISATION
  申请人：ABIDE THERAPEUTICS INC

  公开号：WO2015179559A2

  公开（公告）日：2015-11-26

  Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.